Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis

Sponsor
Gérard Amarenco (Other)
Overall Status
Completed
CT.gov ID
NCT04338646
Collaborator
(none)
150
1
10
15

Study Details

Study Description

Brief Summary

Falls are a common problem in people with multiple sclerosis (PwMS) and can lead to severe consequences (trauma, fear of falling, reduction of social activities). Prevention of falls is one of the priority targets of rehabilitation for PwMS and walking difficulties, which can result of different factors (motor impairment, ataxia, sensitive disorders, fatigability…). Urinary incontinence has been evoked as predictive of falls. But lower urinary tract symptoms (LUTSs) are frequent in PwMS, the prevalence of LUTSs is high (32-96.8%) and increases with MS duration and severity of neurological deficiencies and disabilities. Overactive bladder (OAB) is the most common symptom. Despite its high prevalence and impact on quality of life, the severity of LUTSs has never been studied as specific risk factor of falling. However, urinary urgency and urinary incontinence could lead to precipitation and thus could increase the risk of falling in these patients.

The aim of the study was to assess the relationship between severity of LUTSs and risk of falling in PwMS.

Patients were asked about the number of falls in the past three months and in the past year, and the circumstances in which they occurred (frequency, home, outdoors, going to void, during urinary urgency, nocturia). Severity of LUTSs were assessed by the Urinary Symptoms Profile (USP) Score and patient were classified as with or without urinary incontinence. Number of micturition by night were specifically asked. To take into account motor difficulties and fear of falling, other clinical evaluations were done. The impact of MS on walking was assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS12) questionnaire, the Expanded Disability Status Scale score, and by clinical test with the Time to be Ready to Void (TRV). Fear of falling was assessed by a simple question and with Falls Efficacy Scale-International (FES-I) Questionnaire.

The primary aim was to assess the relationship between severity of LUTSs and occurrence of falls during the past 3 months. The primary outcome was the importance of overactive bladder (OAB) symptoms with OAB USP score. The secondary outcomes were the existence of urinary incontinence, the warning time (defined as the time from the first sensation of urgency to voiding or incontinence), the importance of nocturia and the other scores of USP questionnaire (low stream and stress urinary incontinence).

The secondary aims were to look for the relationship between severity of LUTSs and occurrence of falls during the past year, and to assess the relationship between falls and the classical risk factors of falls.

Condition or Disease Intervention/Treatment Phase
  • Other: Clinical tests

Study Design

Study Type:
Observational
Actual Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Apr 15, 2020
Actual Study Completion Date :
Apr 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Patients enrolled

Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5

Other: Clinical tests
Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void

Outcome Measures

Primary Outcome Measures

  1. Number of falls in the past 3 months [1 day]

    Patients were asked about the number of falls in the past three months, and the circumstances in which they occurred (frequency, home, outdoors, going to void, during urinary urgency, nocturia)

Secondary Outcome Measures

  1. Number of falls in the past year [1 day]

    Patients were asked about the number of falls in the past year, and the circumstances in which they occurred (frequency, home, outdoors, going to void, during urinary urgency, nocturia)

Other Outcome Measures

  1. Correlation between number of falls in the past 3 months and in the past year and clinical datas and characteristics of the patient [1 day]

    The impact of MS on walking was assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS12) questionnaire, the EDSS score, and by clinical test with the Time to be Ready to Void (TRV). Fear of falling was assessed by a simple question and with Falls Efficacy Scale-International (FES-I) Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age ≥ 18 years

  • Multiple sclerosis (MS) diagnosis

  • Lower urinary tract symptoms with or without treatment,

  • Expanded Disability Status Scale score between 1 and 6.5

Exclusion Criteria:
  • relapse of MS in the past month

  • urinary tract infection the day of inclusion

  • impossibility to complete the symptoms' questionnaires

Contacts and Locations

Locations

Site City State Country Postal Code
1 department of Neuro-Urology, Hôpital Tenon Paris France 75020

Sponsors and Collaborators

  • Gérard Amarenco

Investigators

  • Principal Investigator: Gérard Amarenco, PhD, Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gérard Amarenco, Head of Neuro-Urology department, Tenon Hospital, Pierre and Marie Curie University
ClinicalTrials.gov Identifier:
NCT04338646
Other Study ID Numbers:
  • GREEN GRC01 P
First Posted:
Apr 8, 2020
Last Update Posted:
Feb 18, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gérard Amarenco, Head of Neuro-Urology department, Tenon Hospital, Pierre and Marie Curie University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2022